Scarica l'app Stockscreener
98.22
0.78%
-0.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte secures Japanese approval for lymphoma drug Minjuvi - grafa.com
Japan clears Incyte’s Minjuvi for relapsed DLBCL patients - Stock Titan
Incyte StockJefferies nudges target higher after recent gains - AD HOC NEWS
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - Zacks Investment Research
Incyte Corp (INCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incyte Corp (INCY) Institutional Confidence - TradingKey
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Incyte's Vega deal adds VGA039 with $1 billion sales potential by 2034 - S&P Global
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take - Quiver Quantitative
BMO reiterates Incyte stock Underperform on ET/MF trial data - Investing.com UK
BMO reiterates Incyte stock Underperform on ET/MF trial data By Investing.com - Investing.com Nigeria
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - Yahoo Finance
Stifel reiterates Incyte stock rating on drug trial data review - Investing.com
Stifel reiterates Incyte stock rating on drug trial data review By Investing.com - Investing.com Canada
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival - BioSpace
Incyte (INCY) Reports Promising Phase 2 Results for Zilurgiserti - GuruFocus
Incyte (INCY) Shows Promising Phase 3 Trial Results for Tafasita - GuruFocus
Incyte (INCY) Reveals Promising Results for Novel Antibody in Cl - GuruFocus
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Yahoo Finance
INCY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more (BCS:NYSE) - Seeking Alpha
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia - Yahoo Finance
Incyte Stock (US45337C1027): Ownership shifts and pipeline focus keep shares in view - AD HOC NEWS
Lymphoma drug combo cut risk of progression or death 25% - Stock Titan
Incyte reports positive Phase 3 trial results for lymphoma drug - Investing.com
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more - Medical Marketing and Media
Incyte Stock (US45337C1027): Quarterly trends and sector context for US investors - AD HOC NEWS
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings - Investor's Business Daily
Incyte Corporation $INCY Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Incyte bolsters haematology portfolio in $2bn Vega buyout - MSN
Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore! - Smartkarma
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Incyte to Acquire Vega Therapeutics from Star Therapeutics for Up to $2 Billion - Global Legal Chronicle
Why Incyte (INCY) Stock Is Up Today - Yahoo Finance
Incyte (INCY) director Jacqualyn Fouse awarded RSUs and 6,111 stock options - Stock Titan
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal - Investing.com
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Yahoo Finance
INCY Maintains Rating by HC Wainwright & Co. -- Price Target Rai - GuruFocus
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte (NASDAQ:INCY - Benzinga
HC Wainwright Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Incyte to acquire blood disorder drug candidate for $2B - Delaware Business Times
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition - Investing.com
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition By Investing.com - Investing.com UK
Incyte Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Natixis Advisors LLC Purchases 10,795 Shares of Incyte Corporation $INCY - MarketBeat
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):